Evaxion Biotech A/S Investor Relations Material
Latest events
R&D Day 2024
Evaxion Biotech A/S
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Evaxion Biotech A/S
Access all reports
Evaxion Biotech utilizes the AI platform, which is designed to reduce the identification of novel epitopes, and to develop neoantigens, vaccines, and antibody-based therapies; pNLS platform that is designed to identify novel protein structures through computational design; and 2D-to-3D structural similarity searching algorithm. It is developing EB023, a peptide based immunotherapy for the treatment of head and neck cancer. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.
Latest articles
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States